An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

Please provide your email address to receive an email when new articles are posted on . In those with and those without a history of CVD/metabolic disease, patients receiving dupilumab vs. placebo had ...

In a retrospective review of 184 children with atopic dermatitis (AD) treated with dupilumab, four of the 19 who received live-attenuated vaccines experienced adverse events, including one ...

Omalizumab demonstrates superior symptom control in CSU, with 34%-44% achieving complete control in phase 3 trials. Dupilumab, an IL-4Rα antagonist, shows efficacy in CSU, particularly for patients ...